Guggenheim Issues Positive Forecast for BeOne Medicines (NASDAQ:ONC) Stock Price

BeOne Medicines (NASDAQ:ONC) had its price target upped by stock analysts at Guggenheim from $420.00 to $430.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price objective indicates a potential upside of 30.50% from the stock’s current price.

Several other research firms have also recently commented on ONC. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Citigroup reissued an “outperform” rating on shares of BeOne Medicines in a report on Thursday. Zacks Research cut shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 3rd. Nomura upgraded shares of BeOne Medicines to a “strong-buy” rating in a research note on Monday, July 27th. Finally, Morgan Stanley reissued an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BeOne Medicines presently has an average rating of “Moderate Buy” and an average target price of $395.77.

BeOne Medicines Stock Performance

ONC stock traded up $1.97 during trading on Thursday, hitting $329.50. The company had a trading volume of 63,401 shares, compared to its average volume of 279,211. The firm has a market cap of $36.15 billion, a PE ratio of 73.71 and a beta of 0.49. BeOne Medicines has a 1-year low of $253.95 and a 1-year high of $385.22. The firm has a 50-day moving average price of $294.53 and a 200-day moving average price of $308.67. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.65. The firm had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. On average, analysts expect that BeOne Medicines will post 5.93 earnings per share for the current year.

Insider Buying and Selling

In other BeOne Medicines news, CFO Aaron Rosenberg sold 1,157 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $312.71, for a total transaction of $361,805.47. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Chan Henry Lee sold 1,044 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $323.69, for a total value of $337,932.36. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 345,561 shares of company stock worth $105,625,947 in the last quarter. Corporate insiders own 6.19% of the company’s stock.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors have recently bought and sold shares of ONC. EFG International AG purchased a new position in BeOne Medicines in the fourth quarter valued at approximately $25,000. Leonteq Securities AG acquired a new position in BeOne Medicines during the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. purchased a new stake in BeOne Medicines during the second quarter worth approximately $35,000. CWM LLC grew its stake in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the period. Finally, Group One Trading LLC acquired a new stake in shares of BeOne Medicines in the fourth quarter worth $61,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines News Summary

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported earnings of $2.05 per share, exceeding the $1.40 analyst consensus, while revenue reached $1.71 billion versus expectations of $1.66 billion. Revenue reportedly increased 30% year over year, indicating continued momentum in the company’s oncology portfolio. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management now expects full-year revenue of $6.6 billion to $6.8 billion, above the approximately $6.5 billion consensus estimate. The improved outlook suggests management sees sustained demand and operating strength. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analyst target increased: Citizens JMP raised its price target from $396 to $405 and maintained a “market outperform” rating, implying substantial potential upside from recent trading levels. Citizens JMP raises BeOne Medicines price target
• Neutral Sentiment: Insider sale disclosed: CFO Aaron Rosenberg sold 1,157 shares valued at approximately $362,000. The filing stated that the transaction was made to cover tax withholding connected with vested equity awards, making it a limited bearish signal. BeOne Medicines SEC insider filing
• Neutral Sentiment: Valuation remains elevated: Despite the favorable results, the stock trades at a high earnings multiple, leaving shares sensitive to any slowdown in growth or disappointing future guidance.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.